Literature DB >> 17268523

Rituximab in CD20 positive multiple myeloma.

P Moreau, L Voillat, L Benboukher, C Mathiot, C Dumontet, N Robillard, O Hérault, F Garnache, R Garand, N Varoqueaux, H Avet-Loiseau, J L Harousseau, R Bataille.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17268523     DOI： 10.1038/sj.leu.2404558

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes.

Authors:  Rajesh Mukthavaram; Guixin Shi; Santosh Kesari; Dmitri Simberg
Journal:  J Control Release       Date:  2014-03-28       Impact factor: 9.776

Review 2.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

3.  Diagnostic and treatment hurdles in plasma cell myeloma with t(11;14) translocation: A case report.

Authors:  Shun Yin Kong; Wing Kit Lam; Ka Shu Li; Ka Pik Yeung; Chung Yin Ha; Ho Kei Lai; Hay Nun Chan; Yiu Ming Yeung; Sze Fai Yip
Journal:  Mol Clin Oncol       Date:  2018-04-24

Review 4.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

5.  Plasma Cell Dyscrasias in India-2017 Updates.

Authors:  Arihant Jain; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2017-12-13       Impact factor: 0.900

Review 6.  From the bench to the bedside: emerging new treatments in multiple myeloma.

Authors:  Constantine S Mitsiades; Patrick J Hayden; Kenneth C Anderson; Paul G Richardson
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

7.  Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Authors:  Frits van Rhee; Susann M Szmania; Myles Dillon; Anne M van Abbema; Xin Li; Mary K Stone; Tarun K Garg; JuMei Shi; Amberly M Moreno-Bost; Rui Yun; Balaji Balasa; Bishwa Ganguly; Debra Chao; Audie G Rice; Fenghuang Zhan; John D Shaughnessy; Bart Barlogie; Shmuel Yaccoby; Daniel E H Afar
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

8.  Profile of elotuzumab and its potential in the treatment of multiple myeloma.

Authors:  Yi-Chang Liu; Susann Szmania; Frits van Rhee
Journal:  Blood Lymphat Cancer       Date:  2014-06

9.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12

10.  Immunophenotype of normal and myelomatous plasma-cell subsets.

Authors:  Nelly Robillard; Soraya Wuillème; Philippe Moreau; Marie C Béné
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.